Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

At the heart of the event was Organon’s commitment to empowering women through access to safe and effective family planning ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...

Organon (OGN) concluded the recent trading session at $20.18, signifying a +1.05% move from its prior day's close.

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

However, Organon was down 1.4%. Dermavant's Vtama cream, approved by the U.S. Food and Drug Administration in May 2022, treats psoriasis, a common long-term inflammatory skin disease. The FDA is ...